{"id":10270,"date":"2022-07-18T16:00:44","date_gmt":"2022-07-18T15:00:44","guid":{"rendered":"https:\/\/www.x4lifesciences.com\/?p=10270"},"modified":"2022-12-14T09:44:09","modified_gmt":"2022-12-14T09:44:09","slug":"how-vedanta-biosciences-prepared-for-series-d-funding","status":"publish","type":"post","link":"https:\/\/www.x4lifesciences.com\/de\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/","title":{"rendered":"How Vedanta Biosciences prepared for Series D Funding"},"content":{"rendered":"

[vc_row][vc_column][vc_raw_html]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[\/vc_raw_html][\/vc_column][\/vc_row][vc_row full_width=“stretch_row“ el_class=“dark“][vc_column][vc_column_text]<\/p>\n

\n

Daniel Couto is the COO of Vedanta Biosciences, a leading microbiome company who recently completed $68 Million Series D Financing. Dan has nearly 30 years of experience starting and advancing biopharmaceutical development and manufacturing organizations to higher levels of capability, growth and productivity.<\/p>\n<\/p>\n

Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system.<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_raw_html]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[\/vc_raw_html][\/vc_column][\/vc_row][vc_row full_width=“stretch_row“ el_class=“dark“][vc_column][vc_column_text] Daniel Couto is the COO of Vedanta Biosciences, a leading microbiome company who recently completed $68 Million Series D Financing. Dan has…<\/p>\n","protected":false},"author":5,"featured_media":10911,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[239,246],"tags":[318],"class_list":["post-10270","post","type-post","status-publish","format-standard","hentry","category-insights","category-podcast","tag-leadership-learns"],"yoast_head":"\nHow Vedanta Biosciences prepared for Series D Funding - X4 Life Sciences<\/title>\n<meta name=\"description\" content=\"Daniel Couto is the COO of Vedanta Biosciences, a leading microbiome company who recently completed $68 Million Series D Financing. Dan has nearly 30 years of experience starting and advancing biopharmaceutical development and manufacturing organizations to higher levels of capability, growth and productivity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How Vedanta Biosciences prepared for Series D Funding\" \/>\n<meta property=\"og:description\" content=\"Daniel Couto is the COO of Vedanta Biosciences, a leading microbiome company who recently completed $68 Million Series D Financing. Dan has nearly 30 years of experience starting and advancing biopharmaceutical development and manufacturing organizations to higher levels of capability, growth and productivity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"X4 Life Sciences\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-18T15:00:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-14T09:44:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.x4lifesciences.com\/wp-content\/uploads\/sites\/21\/2022\/07\/LAUNCH-POST-1-PETE-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"655\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"dchurch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"dchurch\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/\"},\"author\":{\"name\":\"dchurch\",\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/#\\\/schema\\\/person\\\/37c7cd74386b30bccf2a6c70b6e397e3\"},\"headline\":\"How Vedanta Biosciences prepared for Series D Funding\",\"datePublished\":\"2022-07-18T15:00:44+00:00\",\"dateModified\":\"2022-12-14T09:44:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/\"},\"wordCount\":143,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.x4lifesciences.com\\\/wp-content\\\/uploads\\\/sites\\\/21\\\/2022\\\/07\\\/LAUNCH-POST-1-PETE-2.jpg\",\"keywords\":[\"Leadership Learns\"],\"articleSection\":[\"Insights\",\"Podcast\"],\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/\",\"url\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/\",\"name\":\"How Vedanta Biosciences prepared for Series D Funding - X4 Life Sciences\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.x4lifesciences.com\\\/wp-content\\\/uploads\\\/sites\\\/21\\\/2022\\\/07\\\/LAUNCH-POST-1-PETE-2.jpg\",\"datePublished\":\"2022-07-18T15:00:44+00:00\",\"dateModified\":\"2022-12-14T09:44:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/#\\\/schema\\\/person\\\/37c7cd74386b30bccf2a6c70b6e397e3\"},\"description\":\"Daniel Couto is the COO of Vedanta Biosciences, a leading microbiome company who recently completed $68 Million Series D Financing. Dan has nearly 30 years of experience starting and advancing biopharmaceutical development and manufacturing organizations to higher levels of capability, growth and productivity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.x4lifesciences.com\\\/wp-content\\\/uploads\\\/sites\\\/21\\\/2022\\\/07\\\/LAUNCH-POST-1-PETE-2.jpg\",\"contentUrl\":\"https:\\\/\\\/www.x4lifesciences.com\\\/wp-content\\\/uploads\\\/sites\\\/21\\\/2022\\\/07\\\/LAUNCH-POST-1-PETE-2.jpg\",\"width\":1200,\"height\":655},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/2022\\\/07\\\/18\\\/how-vedanta-biosciences-prepared-for-series-d-funding\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.x4lifesciences.com\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How Vedanta Biosciences prepared for Series D Funding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/#website\",\"url\":\"https:\\\/\\\/www.x4lifesciences.com\\\/\",\"name\":\"X4 Life Sciences\",\"description\":\"Life Sciences Recruitment Specialists\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.x4lifesciences.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.x4lifesciences.com\\\/#\\\/schema\\\/person\\\/37c7cd74386b30bccf2a6c70b6e397e3\",\"name\":\"dchurch\",\"url\":\"https:\\\/\\\/www.x4lifesciences.com\\\/de\\\/author\\\/dchurch\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How Vedanta Biosciences prepared for Series D Funding - X4 Life Sciences","description":"Daniel Couto is the COO of Vedanta Biosciences, a leading microbiome company who recently completed $68 Million Series D Financing. Dan has nearly 30 years of experience starting and advancing biopharmaceutical development and manufacturing organizations to higher levels of capability, growth and productivity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/","og_locale":"de_DE","og_type":"article","og_title":"How Vedanta Biosciences prepared for Series D Funding","og_description":"Daniel Couto is the COO of Vedanta Biosciences, a leading microbiome company who recently completed $68 Million Series D Financing. Dan has nearly 30 years of experience starting and advancing biopharmaceutical development and manufacturing organizations to higher levels of capability, growth and productivity.","og_url":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/","og_site_name":"X4 Life Sciences","article_published_time":"2022-07-18T15:00:44+00:00","article_modified_time":"2022-12-14T09:44:09+00:00","og_image":[{"width":1200,"height":655,"url":"https:\/\/www.x4lifesciences.com\/wp-content\/uploads\/sites\/21\/2022\/07\/LAUNCH-POST-1-PETE-2.jpg","type":"image\/jpeg"}],"author":"dchurch","twitter_card":"summary_large_image","twitter_misc":{"Written by":"dchurch","Est. reading time":"1 Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/#article","isPartOf":{"@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/"},"author":{"name":"dchurch","@id":"https:\/\/www.x4lifesciences.com\/#\/schema\/person\/37c7cd74386b30bccf2a6c70b6e397e3"},"headline":"How Vedanta Biosciences prepared for Series D Funding","datePublished":"2022-07-18T15:00:44+00:00","dateModified":"2022-12-14T09:44:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/"},"wordCount":143,"commentCount":0,"image":{"@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/www.x4lifesciences.com\/wp-content\/uploads\/sites\/21\/2022\/07\/LAUNCH-POST-1-PETE-2.jpg","keywords":["Leadership Learns"],"articleSection":["Insights","Podcast"],"inLanguage":"de-DE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/","url":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/","name":"How Vedanta Biosciences prepared for Series D Funding - X4 Life Sciences","isPartOf":{"@id":"https:\/\/www.x4lifesciences.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/#primaryimage"},"image":{"@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/www.x4lifesciences.com\/wp-content\/uploads\/sites\/21\/2022\/07\/LAUNCH-POST-1-PETE-2.jpg","datePublished":"2022-07-18T15:00:44+00:00","dateModified":"2022-12-14T09:44:09+00:00","author":{"@id":"https:\/\/www.x4lifesciences.com\/#\/schema\/person\/37c7cd74386b30bccf2a6c70b6e397e3"},"description":"Daniel Couto is the COO of Vedanta Biosciences, a leading microbiome company who recently completed $68 Million Series D Financing. Dan has nearly 30 years of experience starting and advancing biopharmaceutical development and manufacturing organizations to higher levels of capability, growth and productivity.","breadcrumb":{"@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/#primaryimage","url":"https:\/\/www.x4lifesciences.com\/wp-content\/uploads\/sites\/21\/2022\/07\/LAUNCH-POST-1-PETE-2.jpg","contentUrl":"https:\/\/www.x4lifesciences.com\/wp-content\/uploads\/sites\/21\/2022\/07\/LAUNCH-POST-1-PETE-2.jpg","width":1200,"height":655},{"@type":"BreadcrumbList","@id":"https:\/\/www.x4lifesciences.com\/2022\/07\/18\/how-vedanta-biosciences-prepared-for-series-d-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.x4lifesciences.com\/de\/"},{"@type":"ListItem","position":2,"name":"How Vedanta Biosciences prepared for Series D Funding"}]},{"@type":"WebSite","@id":"https:\/\/www.x4lifesciences.com\/#website","url":"https:\/\/www.x4lifesciences.com\/","name":"X4 Life Sciences","description":"Life Sciences Recruitment Specialists","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.x4lifesciences.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Person","@id":"https:\/\/www.x4lifesciences.com\/#\/schema\/person\/37c7cd74386b30bccf2a6c70b6e397e3","name":"dchurch","url":"https:\/\/www.x4lifesciences.com\/de\/author\/dchurch\/"}]}},"_links":{"self":[{"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/posts\/10270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/comments?post=10270"}],"version-history":[{"count":3,"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/posts\/10270\/revisions"}],"predecessor-version":[{"id":10358,"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/posts\/10270\/revisions\/10358"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/media\/10911"}],"wp:attachment":[{"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/media?parent=10270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/categories?post=10270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.x4lifesciences.com\/de\/wp-json\/wp\/v2\/tags?post=10270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}